MAPT and Alzheimer disease: Our work demonstrates the potential for the clinical utility of FDG-PET to be extended beyond differential diagnosis of FTD-spectrum, AD-spectrum and the DLB-spectrum to additional utility in stratifying patients on the AD-spectrum by tau load to facilitate complex clinical decision-making.